- Home
- BEAM vs NAMS Comparison
BEAM vs NAMS Comparison
Compare BEAM & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- NAMS
- Stock Information
- Founded
- BEAM 2017
- NAMS 2019
- Country
- BEAM United States
- NAMS Netherlands
- Employees
- BEAM N/A
- NAMS N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- BEAM Health Care
- NAMS Health Care
- Exchange
- BEAM Nasdaq
- NAMS Nasdaq
- Market Cap
- BEAM 1.8B
- NAMS 2.2B
- IPO Year
- BEAM 2020
- NAMS N/A
- Fundamental
- Price
- BEAM $16.19
- NAMS $18.93
- Analyst Decision
- BEAM Strong Buy
- NAMS Strong Buy
- Analyst Count
- BEAM 11
- NAMS 6
- Target Price
- BEAM $48.90
- NAMS $42.83
- AVG Volume (30 Days)
- BEAM 1.9M
- NAMS 689.2K
- Earning Date
- BEAM 05-06-2025
- NAMS 05-08-2025
- Dividend Yield
- BEAM N/A
- NAMS N/A
- EPS Growth
- BEAM N/A
- NAMS N/A
- EPS
- BEAM N/A
- NAMS N/A
- Revenue
- BEAM $63,578,000.00
- NAMS $47,140,000.00
- Revenue This Year
- BEAM N/A
- NAMS N/A
- Revenue Next Year
- BEAM $10.59
- NAMS N/A
- P/E Ratio
- BEAM N/A
- NAMS N/A
- Revenue Growth
- BEAM N/A
- NAMS 586.97
- 52 Week Low
- BEAM $13.53
- NAMS $14.06
- 52 Week High
- BEAM $35.25
- NAMS $27.29
- Technical
- Relative Strength Index (RSI)
- BEAM 39.35
- NAMS 54.33
- Support Level
- BEAM $15.35
- NAMS $16.95
- Resistance Level
- BEAM $17.47
- NAMS $19.58
- Average True Range (ATR)
- BEAM 0.90
- NAMS 0.96
- MACD
- BEAM -0.07
- NAMS -0.03
- Stochastic Oscillator
- BEAM 24.71
- NAMS 76.20
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.